• Reduce major adverse cardiac events
• Improve rates of target vessel revascularization
• Reduce rates of target lesion failure and stent thrombosis
• Enhance outcomes in diabetic patients
Various estimates exist on the number of diabetics in the United States. According to the Centers for Disease Control and Prevention (CDC), 23.6 million Americans, or 7.8 percent of the population, has
diabetes. The illness commonly is linked with heart disease, with doctors estimating that diabetes doubles a person’s risk of developing heart disease. CDC statistics indicate that heart attacks account for 60 percent of deaths in diabetics, while strokes are responsible for 25 percent of deaths. Such statistics put the diabetic population at high risk for cardiovascular disorders. DES manufacturers hope their stents can help reduce the risk of heart disease in diabetics, and are seeking approval for this indication from the U.S. Food and Drug Administration.
Stent Market Shares and Revenues
Boston Scientific and Abbott Vascular recently reported revenue data for fiscal 2009. Data Decision Group has analyzed and collated this information to provide the following estimates in the pie chart below:
Combining these results leaves Boston Scientific with 2009 worldwide revenues of $1.8 billion and an increase of 1.5 percent compared with 2008. This is impressive in a market where every share point is worth approximately $20 million.
Also impressive is Abbott Vascular’s Xience V sales, estimated in this report to total $520 million. This year will be a critical turning point for Boston Scientific and Abbott Vascular. While the Taxus stent lost its market leadership position, Boston Scientific has maintained a robust position in the market because it also sells the Abbott Vascular Xience stent under the name Promus.
This arrangement resulted from a profit-sharing deal Abbott developed when Boston Scientific acquired Guidant Corp. in 2006. Market share estimates for July 2009 show Xience and Promus holding more than half the U.S. market combined, according to Abbott data. Taxus Liberte was in third place with a 20 percent market share, followed by Johnson & Johnson and Medtronic’s Endeavor.
The fight for global market share is complex and will continue in 2010. Ownership will depend on many factors, including new indications and approvals, new products from existing manufacturers, possible new competitors in the international market, clinical trial results and licensing changes. The $4.8 billion worldwide market is critical to interventional cardiology device leadership and its four major players will battle over every market share point.
References
1. K. Winstein, 2009 Dow Jones & Company, Inc, J. Kamp, 2009 Dow Jones & Company Inc., Press Release: Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31, 2009.
2. Press Release: Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31, 2009.
3. Press Release: Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31, 2009.
4. www.news-medical.net/news/20090924/COMPARE-trial-results-demonstrate-higher-efficacy- of-XIENCE-V-stent-system.aspx.